Compare Cadila Healthcare with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs SUVEN LIFESCIENCES - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE SUVEN LIFESCIENCES CADILA HEALTHCARE/
SUVEN LIFESCIENCES
 
P/E (TTM) x 14.8 19.4 76.3% View Chart
P/BV x 2.9 3.9 73.5% View Chart
Dividend Yield % 1.4 0.5 264.4%  

Financials

 CADILA HEALTHCARE   SUVEN LIFESCIENCES
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
SUVEN LIFESCIENCES
Mar-19
CADILA HEALTHCARE/
SUVEN LIFESCIENCES
5-Yr Chart
Click to enlarge
High Rs558338 165.2%   
Low Rs362169 213.4%   
Sales per share (Unadj.) Rs116.352.1 223.1%  
Earnings per share (Unadj.) Rs17.96.8 261.6%  
Cash flow per share (Unadj.) Rs23.18.6 269.9%  
Dividends per share (Unadj.) Rs3.501.50 233.3%  
Dividend yield (eoy) %0.80.6 128.7%  
Book value per share (Unadj.) Rs85.465.3 130.8%  
Shares outstanding (eoy) m1,023.74127.28 804.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.04.9 81.3%   
Avg P/E ratio x25.737.1 69.3%  
P/CF ratio (eoy) x19.929.6 67.2%  
Price / Book Value ratio x5.43.9 138.6%  
Dividend payout %19.622.0 89.2%   
Avg Mkt Cap Rs m470,66432,272 1,458.4%   
No. of employees `00011.81.1 1,092.3%   
Total wages/salary Rs m18,545661 2,804.7%   
Avg. sales/employee Rs Th10,072.76,132.2 164.3%   
Avg. wages/employee Rs Th1,569.1611.1 256.8%   
Avg. net profit/employee Rs Th1,547.7803.5 192.6%   
INCOME DATA
Net Sales Rs m119,0496,635 1,794.3%  
Other income Rs m1,132242 467.2%   
Total revenues Rs m120,1816,877 1,747.5%   
Gross profit Rs m28,4751,604 1,775.0%  
Depreciation Rs m5,388221 2,433.6%   
Interest Rs m91138 2,416.4%   
Profit before tax Rs m23,3081,587 1,468.3%   
Minority Interest Rs m6280-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,644718 786.1%   
Profit after tax Rs m18,292869 2,104.0%  
Gross profit margin %23.924.2 98.9%  
Effective tax rate %24.245.2 53.5%   
Net profit margin %15.413.1 117.3%  
BALANCE SHEET DATA
Current assets Rs m82,0056,232 1,315.8%   
Current liabilities Rs m60,7201,490 4,074.9%   
Net working cap to sales %17.971.5 25.0%  
Current ratio x1.44.2 32.3%  
Inventory Days Days7386 84.6%  
Debtors Days Days9883 119.0%  
Net fixed assets Rs m83,7034,043 2,070.2%   
Share capital Rs m1,024127 804.4%   
"Free" reserves Rs m86,4218,183 1,056.1%   
Net worth Rs m87,4458,310 1,052.3%   
Long term debt Rs m25,55118 143,544.9%   
Total assets Rs m180,65310,389 1,738.9%  
Interest coverage x26.643.1 61.7%   
Debt to equity ratio x0.30 13,641.1%  
Sales to assets ratio x0.70.6 103.2%   
Return on assets %10.68.7 121.7%  
Return on equity %20.910.5 199.9%  
Return on capital %22.019.5 112.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m42,6835,622 759.2%   
Fx outflow Rs m11,2421,799 624.8%   
Net fx Rs m31,4413,822 822.6%   
CASH FLOW
From Operations Rs m9,193356 2,585.9%  
From Investments Rs m-9,737-279 3,495.0%  
From Financial Activity Rs m515-225 -228.8%  
Net Cashflow Rs m-29-148 19.6%  

Share Holding

Indian Promoters % 74.8 63.4 118.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 0.0 -  
FIIs % 5.9 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 36.5 30.1%  
Shareholders   44,069 37,287 118.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   ELDER PHARMA  TTK HEALTHCARE  ORCHID PHARMA LTD  DISHMAN PHARMA  J.B.CHEMICALS  

Compare CADILA HEALTHCARE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Sep 20, 2019 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS